close 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse. Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Change languageEesti
Ülevaade

SAN

81.05

-0.34%↓

SAN

81.05

-0.34%↓

SAN

81.05

-0.34%↓

SAN

81.05

-0.34%↓

SAN

81.05

-0.34%↓

Kodu・Aktsiate loetelu・Nanobiotix
Search

Nanobiotix

Suletud

18.2 0.44

Osta

Hinna uuendus 4. veebr 2026, 16:29 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.78

Max

18.6

Põhinäitajad

By Trading Economics

Sissetulek

-5.4M

Müük

27M

Kasumimarginaal

-20.208

Töötajad

103

EBITDA

1.1M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+25.96% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

1. apr 2026

Turustatistika

By TradingEconomics

Turukapital

860M

Eelmine avamishind

17.76

Eelmine sulgemishind

18.2

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. veebr 2026, 00:00 UTC

Kuumad aktsiad

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

DJ

Loe

4. veebr 2026, 22:55 UTC

Tulu

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

DJ

Loe

4. veebr 2026, 21:44 UTC

Tulu

Arm Holdings 3Q Profit Falls Despite Revenue Growth

DJ

Loe

4. veebr 2026, 21:39 UTC

Tulu

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

DJ

Loe

5. veebr 2026, 00:00 UTC

Tulu

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

DJ

Loe

5. veebr 2026, 00:00 UTC

Tulu

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

DJ

Loe

4. veebr 2026, 23:46 UTC

Market Talk

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

DJ

Loe

4. veebr 2026, 23:45 UTC

Tulu

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

DJ

Loe

4. veebr 2026, 23:32 UTC

Market Talk

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

DJ

Loe

4. veebr 2026, 22:59 UTC

Omandamised, ülevõtmised, äriostud

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

DJ

Loe

4. veebr 2026, 22:30 UTC

Tulu

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

DJ

Loe

4. veebr 2026, 22:30 UTC

Tulu

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

DJ

Loe

4. veebr 2026, 22:21 UTC

Tulu

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

DJ

Loe

4. veebr 2026, 22:17 UTC

Market Talk

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

DJ

Loe

4. veebr 2026, 22:15 UTC

Market Talk

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

DJ

Loe

4. veebr 2026, 22:00 UTC

Market Talk

ESG Roundup: Market Talk

DJ

Loe

4. veebr 2026, 21:53 UTC

Tulu

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

DJ

Loe

4. veebr 2026, 21:51 UTC

Tulu

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

DJ

Loe

4. veebr 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

DJ

Loe

4. veebr 2026, 21:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

DJ

Loe

4. veebr 2026, 21:50 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

DJ

Loe

4. veebr 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

DJ

Loe

4. veebr 2026, 21:45 UTC

Tulu

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

DJ

Loe

4. veebr 2026, 21:44 UTC

Tulu

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

DJ

Loe

4. veebr 2026, 21:43 UTC

Tulu

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

DJ

Loe

4. veebr 2026, 21:41 UTC

Tulu

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

DJ

Loe

4. veebr 2026, 21:36 UTC

Market Talk

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

DJ

Loe

4. veebr 2026, 21:30 UTC

Tulu

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

DJ

Loe

4. veebr 2026, 21:30 UTC

Tulu

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

DJ

Loe

4. veebr 2026, 21:30 UTC

Tulu

Beach Energy Interim Dividend 1 Australian Cent/Sjare

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

25.96% tõus

12 kuu keskmine prognoos

Keskmine 23 EUR  25.96%

Kõrge 23 EUR

Madal 23 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

1

Osta

0

Hoia

0

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Recent bullish events outweigh bearish events.

Keskpikk perspektiiv

Weak Bearish Evidence

Bearish events outweigh bullish events.

Pikk perspektiiv

Weak Bearish Evidence

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Muud aktsiad sektorist

SAN

Sanofi SA

81.05

↓-0.34%
help-icon Live chat